| Original language | English (US) |
|---|---|
| Pages (from-to) | 3132-3135 |
| Number of pages | 4 |
| Journal | Blood Advances |
| Volume | 3 |
| Issue number | 20 |
| DOIs | |
| State | Published - Oct 22 2019 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood Advances, Vol. 3, No. 20, 22.10.2019, p. 3132-3135.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma
AU - Kamdar, Manali
AU - Li, Hongli
AU - Chen, Robert W.
AU - Rimsza, Lisa M.
AU - Leblanc, Michael L.
AU - Fenske, Timothy S.
AU - Shea, Thomas C.
AU - Barr, Paul M.
AU - Phillips, Tycel J.
AU - Leonard, John P.
AU - Kahl, Brad S.
AU - Friedberg, Jonathan W.
AU - Smith, Sonali M.
N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA180888, CA180819, CA180821, CA180820, CA180838, CA189957, CA189821, CA189972, CA189953, CA180846, CA180835, CA189808, CA46368, and CA11083 and in part by Sequenta, Inc. (Adaptive Biotechnologies). Funding Information: Conflict-of-interest disclosure: M.K. is on the speakers bureau of Seattle Genetics and has received consultancy fees Gen-entech, AstraZeneca, and Celgene. R.W.C. has received consultancy fees from Millennium Pharmaceuticals and research funding from Affimed; consultancy, honoraria, and speakers bureau fees and research funding from Seattle Genetics; consultancy fees and research funding from Pharmacyclics and Merck; and consultancy and speakers bureau fees and research funding from Genentech. L.M.R. is an inventor on the patent for the Lymph2Cx assay (NanoString). P.M.B. has received consultancy fees from Pharmacyclics, AbbVie, Gilead, Merck, Seattle Genetics, Genentech, Celgene, Verastem, TG Therapeutics, and Janssen. T.J.P. has received consultancy fees from Genentech, Seattle Genetics, Bayer, Gilead, and Pharmacyclics and research funding from AbbVie. J.P.L. has received consultancy fees from Sutro, Bayer, Gilead, AstraZeneca, Celgene, Merck, Morphosys, Beigene, Nordic Nanovector, Roche/Genentech, ADC Therapeutics, Sandoz, Karyopharm, Miltenyi, and Akcea Therapeutics. B.S.K. has received consultancy fees from Seattle Genetics, AstraZeneca, Gilead, AbbVie, Celgene, Acerta, CTI, Juno, ADC Therapeutics, and Genentech. J.W.F. has received honoraria from Bayer. S.M.S. has received honoraria from Por-tola and consultancy fees from BMS. The remaining authors declare no competing financial interests.
PY - 2019/10/22
Y1 - 2019/10/22
UR - http://www.scopus.com/inward/record.url?scp=85074915718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074915718&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2019000526
DO - 10.1182/bloodadvances.2019000526
M3 - Article
C2 - 31648328
AN - SCOPUS:85074915718
SN - 2473-9529
VL - 3
SP - 3132
EP - 3135
JO - Blood Advances
JF - Blood Advances
IS - 20
ER -